VentriPoint Diagnostics Ltd. Stock price

Equities

VPT

CA92281P2008

Advanced Medical Equipment & Technology

Market Closed - Toronto S.E. 03:56:16 2024-03-28 pm EDT 5-day change 1st Jan Change
0.225 CAD 0.00% Intraday chart for VentriPoint Diagnostics Ltd. -6.25% -23.73%
Sales 2021 - Sales 2022 68.17K 50.33K Capitalization 42.34M 31.27M
Net income 2021 -3M -2.22M Net income 2022 -4M -2.95M EV / Sales 2021 -
Net cash position 2021 9.11M 6.73M Net cash position 2022 4.73M 3.49M EV / Sales 2022 552 x
P/E ratio 2021
-12.1 x
P/E ratio 2022
-8.64 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 97.84%
More Fundamentals * Assessed data
Dynamic Chart
Ventripoint Diagnostics Ltd. Releases Significant Upgrade to the Design and Function of Its Whole-Heart Analysis System (VMS+3.2) CI
Ventripoint Diagnostics Ltd. Showcases A.I. Powered Heart-Scanning Technology at International Cardiology Conferences CI
Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as Interim CEO CI
Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as President CI
The Paediatric Heart Centre At the Medical University of Vienna Has Chosen to Adopt the Vms+ as Its Cardiac Diagnostic Tool CI
VentriPoint Diagnostics Ltd. Announces Appointment of Dr. Luc Mertens to Clinical Advisory Board CI
VentriPoint Diagnostics Ltd. Enters into A Global Distribution and Marketing Agreement with Ascend Cardiovascular CI
VentriPoint Diagnostics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
VentriPoint Diagnostics Ltd. Announces Executive Changes CI
VentriPoint Diagnostics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Ventripoint Welcomes Evelina London Children's Hospital as Newest Vms+ User CI
Ventripoint Diagnostics Ltd. Announces That Ventripoint and Ascend Cardiovascular, Llc Have Developed A New Integrated Product CI
Ventripoint Diagnostics Ltd. Announces Collaboration with Ascend Cardiovascular CI
VentriPoint Diagnostics Ltd. Announces Purchase of VMS+ by Medical Center ­University of Freiburg CI
VentriPoint Diagnostics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news
1 week-6.25%
Current month-18.18%
1 month-25.00%
3 months-27.42%
6 months+15.38%
Current year-23.73%
More quotes
1 week
0.22
Extreme 0.215
0.24
1 month
0.22
Extreme 0.215
0.30
Current year
0.22
Extreme 0.215
0.36
1 year
0.12
Extreme 0.12
0.36
3 years
0.12
Extreme 0.12
0.67
5 years
0.07
Extreme 0.065
0.67
10 years
0.07
Extreme 0.065
1.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - Feb. 04
Director of Finance/CFO 55 20-06-02
Chairman 76 10-09-30
Members of the board TitleAgeSince
Director/Board Member - 19-12-16
Director/Board Member - 21-12-19
Chairman 76 10-09-30
More insiders
Date Price Change Volume
24-03-28 0.225 0.00% 42 900
24-03-27 0.225 -2.17% 71,200
24-03-26 0.23 +2.22% 28,998
24-03-25 0.225 -2.17% 59,500
24-03-22 0.23 -4.17% 68,260

Delayed Quote Toronto S.E., March 28, 2024 at 03:56 pm EDT

More quotes
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).
More about the company
  1. Stock
  2. Equities
  3. Stock VentriPoint Diagnostics Ltd. - Toronto S.E.